Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 9/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15400983 | 0.83 | PIM1 (0.46) | PIM1PIM3PIM2MAP4K1IRAK4 | |
| SCHEMBL15403672 | 0.79 | IRAK4 (0.53) | PIM1PIM3PIM2IRAK4 | |
| SCHEMBL15400777 | 0.79 | PIM1 (0.38) | PIM1PIM3PIM2MAP4K1IRAK4 | |
| SCHEMBL15401430 | 0.78 | PIM1 (0.37) | PIM1PIM3PIM2MAP4K1 | |
| SCHEMBL17441195 | 0.75 | IRAK4 (0.62) | MAPTIRAK4 | |
| SCHEMBL15400761 | 0.75 | PIM1 (0.39) | PIM1PIM3PIM2MAP4K1IRAK4 | |
| SCHEMBL15401165 | 0.75 | PIM1 (0.67) | PIM1PIM3PIM2MAP4K1 | |
| SCHEMBL24852360 | 0.74 | KHK (0.49) | PIM1PIM3PIM2MAP4K1MAPT | |
| SCHEMBL31738193 | 0.74 | KHK (0.49) | PIM1PIM3PIM2MAP4K1MAPT | |
| SCHEMBL15400704 | 0.73 | PIM1 (0.70) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867232-B1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2018-08-08 | — | — | EP | disclosed |
| EP-2867232-B1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | GENENTECH,INC. | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | PIM1 1/4885PIM3 2/4885PIM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.